Specialised clinic to offer regular device monitoring, battery assessment, rhythm evaluation, and expert cardiac electrophysiology consultation
The industry is expected to grow significantly over the next few years as healthcare accessibility improves and insurance penetration increases
New platform integrates advanced cardiac mapping and ablation workflow, offering a novel treatment option for AFib patients at risk of stroke and heart failure
Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials is the bioequivalent to the reference listed drug (RLD) Halaven injection of Eisai, Inc.
Regulatory clearance strengthens company’s global footprint and expands access to the Australian animal healthcare market
New PARTNER trial sub-study data show that post-operative ctDNA detection using tumour-informed MRD assays can accurately predict distant recurrence risk in triple-negative breast cancer patients
DCGI-approved semaglutide syringes for diabetes and obesity expand treatment choices and improve affordability
The hospital successfully treats two complex high-risk cardiac patients using advanced minimally invasive heart surgeries
The approval is expected to support the company’s presence in regulated international markets and further strengthen its position as a reliable pharma manufacturing partner
A first-of-its-kind national platform honouring the people and institutions shaping the next chapter of life sciences in India
Subscribe To Our Newsletter & Stay Updated
